Cellebrite

NOVEMBER 2026

Investor Presentation.

Introduction to Cellebrite

© 2026 Cellebrite DI Ltd.

Disclaimer.

This presentation has been prepared by Cellebrite DI Ltd. (the "Company") solely for informational purposes. It is not, and should not be assumed to be, complete. This presentation is not an offer to sell securities, nor is it a solicitation of an offer to buy securities. This presentation is not directed at, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. Persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. In considering any performance information contained herein, you should bear in mind that past or projected performance is not necessarily indicative of future results, and there can be no assurance that any entity referenced herein will achieve comparable results or that illustrative returns, if any, will be met. Statements in this presentation are made as of the date this presentation is made unless stated otherwise, and the delivery of this presentation at any time shall under no circumstances create an implication that the information contained herein is correct as of any time after such date.

Use of Non-GAAP Financial Measures

This Presentation includes non-GAAP financial measures. Cellebrite believes that these non-GAAP measures are useful to investors for two principal reasons. First, Cellebrite believes these measures may assist investors in comparing performance over various reporting periods on a consistent basis by removing from operating results the impact of items that do not reflect core operating performance. Second, these measures are used by Cellebrite's management to assess its performance. Cellebrite believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends. These non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Other companies may calculate these non-GAAP financial measures differently, and therefore such financial measures may not be directly comparable to similarly titled measures of other companies. A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this Presentation and is also available in our earnings release for the quarter on our website at investors.cellebrite.com.

In regard to forward looking non-GAAP guidance, we are not able to reconcile the forward-looking Adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items.

Forward-Looking Statements

This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "will," "appear," "approximate," "foresee," "might," "possible," "potential," "believe," "could," "predict," "should," "could," "continue," "expect," "estimate," "may," "plan," "outlook," "future" and "project" and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, estimated financial information for the second quarter of 2026 and for fiscal year 2026 including those statements with respect to our 2026 outlook as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite's business. These statements are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's digital investigation solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; Cellebrite's dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite's dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with our ability to obtain CFIUS approval for the acquisition of Corellium and with our ongoing compliance with national security agreements entered into with the U.S. government; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled "Risk Factors" in Cellebrite's annual report on Form 20-F filed with the SEC on March 3, 2026, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ("SEC"), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.



© 2026 Cellebrite DI Ltd.

Mission


Protect Communities, Nations and Businesses.

We deliver the industry's most comprehensive set of solutions that enable law enforcement, defense and intelligence agencies, and enterprises worldwide to convert digital data into actionable intelligence, accelerating investigations, enhancing sovereign security, elevating operational efficacy and efficiency and enabling advanced mobile research and application security.


Platform

Comprehensive Solutions for Investigations, Intelligence and Operations.

Cellebrite's purpose-built platform is increasingly integrated and delivered via a scalable, secure cloud infrastructure that leverages deep domain expertise in mobile device data, trusted workflows that protect the chain of custody, proven legal and forensic integrity, strict security and compliance protocols, and responsible AI-powered analytical insights.



© 2026 Cellebrite DI Ltd.



Collect

- Unlock
- Extract
- Decode
- Automate
- Lab
- Field
- Drones

Manage

- Store
- Collaborate
- Evidence MNGT.
- Case MNGT.



Virtualize

- Vulnerability Research
- App Security
- Automotive
- Industrial Systems
- Device Replication

AI

- Multi-data Source
- Multi-device
- GenAI
- Agentic AI

© 2026 Cellebrite DI Ltd.

Addressing Customer Challenges.

© 2026 Cellebrite DI Ltd.

The Rising Public Safety Gap: Powerful Macro Tailwinds

↑ **Digital Evidence**

↑ **Case Load**

(data volumes and cases)

↑ **Criminal Technical Sophistication**

↑ **Public Scrutiny**




- Static case closure rates
- Skills gap of agency staff
- Escalating officer attrition & burnout
- Funding challenges

© 2026 Cellebrite DI Ltd.

Today's Digital Investigations: Powerful Demand Drivers

Typical Investigation Time by Stage



** Real-Time Crime Index
** 2026 Cellebrite Industry Trends Survey

01. Data Volume & Complexity

- Constant crime rate and an increasing population* (leading to higher case load)
- 97% cite smartphones as the top evidence source**
- 94% say complexity strains caseloads**
- The average monthly number of extractions has increased by 44% over the past 2 years
- Delivery timelines for mobile device data remain extended**

02. Inefficient Processes

- Review & analysis consumes up to 60% of an investigation, with 70% still relying on manual review**
- Up to two-thirds of examiners still share digital evidence on portable hard drives and USB sticks**
- Correlating data across disparate sources can be time consuming and challenging, especially without the right analytical tools**

03. Ethics & Accountability

- Ever-increasing public scrutiny
- Technology provider focus on data privacy
- Artificial Intelligence use in Law Enforcement and Criminal Activity

© 2026 Cellebrite DI Ltd.

Our Customers Care About Time.

Cellebrite Delivers.

Time-to-Data	→ **Faster access to more devices. Extraction of more data.**
Time-to-Insights	→ **Faster examinations. More actionable, high-value information.**
Time-to-Collaboration	→ **Greater efficiency and productivity.**
Time-to-Evidence	→ **Faster analysis. A high-fidelity chain of custody.**
Time-to-Justice	→ **Faster closure of more cases.**
Time-to-Intelligence	→ **Faster visibility into device vulnerabilities and application security.**
Time-to-Action	→ **Accelerated insights support sharper decisions and decisive action.**



© 2026 Cellebrite DI Ltd.



50k Images and Video

250 Chat Parties,
Millions of Messages

60% of All
Internet Traffic

Over 30
Communication Apps

10 Apps Actively
Used / Day


120 Hours of Voice

10 to 15 Social Accounts

4.5 Hours Screen
Time / Day

Virtually all crime has a digital component.

Cellebrite AI increases investigative speed & efficiency across an expanding range of evidence sources



Cellebrite AI

- → Language Agnostic
- → Multimodal Analysis
- → Native Media Analytics
- → Scalability

Image Classification & Similarity

Topic Detection

Built-in Translation

Message Summarization

Location Corroboration

Speech To Text

Identity Resolution

Web Browser History Summary


Multi-communication Platform Analysis

© 2026 Cellebrite DI Ltd.

- Terrorism
- Cybercrime
- Homicide
- Narcotics
- Child Exploitation
- Human Trafficking

Why **Cellebrite AI**

- → Full traceability, ethical use, and human verification
- → Security, Privacy and Chain-of-Custody
- → Legal, Forensics and Regulatory Standards
- → Proprietary Data Access & Extraction





RAPID ACTIONABLE INSIGHTS

Unique intimacy with the most complex evidential artifacts.

Domain expertise with investigative workflows leveraged by hundreds of man years of law enforcement.

Trusted by thousands of the largest and most sophisticated public safety and government agencies around the world.

Data optimized for CLBT Platform.

Integrated and secure Cloud Ecosystem.

© 2026 Cellebrite DI Ltd.

Cellebrite AI: Genesis in Action.

A homicide tied to a wider gang network.


A Major Crimes Division used Genesis on a homicide investigation, linking a confidential tip, surveillance footage, a forensic vehicle exam and ballistics. It tied the weapons through a nationwide ballistics database to a wider gang network. Genesis also quickly produce a crime-scene map and a movement timeline that further assisted detectives.

Surfacing a murder confession and cover up plans.

A Florida detective recently shared that Genesis helped analysts search two years of jail calls and, in just 15 minutes, surface a murder confession and plans for a cover-up. For this detective, Genesis was the difference between evidence that exists and evidence that is found.

"Over nearly 20 years of effectively combining criminal investigation with digital forensics and analysis. GENESIS is the finest digital evidence product I have ever used."

Leadership | Counterterrorism Unit
Regional Police Force (APAC)



"Genesis is not a luxury tool … it is a critical resource especially in time-sensitive cases."

Detective
County Sheriff's Office (USA)

Months of financial review compressed into hours.

An investigator uploaded the financial records of a condominium association executive accused of misappropriating HOA funds. Reviewing, compiling and analyzing them manually usually takes weeks or even months. Not only did Genesis replicate and validate the manual analysis in hours but it also helped determine restitution recommendations.

Hundreds of hours of prison calls, 200 illegal weapons.

A major metropolitan police force uploaded three months of recorded prison calls from five inmates. Genesis cut through the audio to isolate the roughly three minutes where firearms were discussed. Those three minutes alone led investigators to three addresses, the recovery of 200 firearms and three additional arrests

© 2026 Cellebrite DI Ltd.


Example 01

EMEA:
Regional Law Enforcement Agency


A regional forensics lab servicing multiple police departments in EMEA turned to Cellebrite for a scalable ecosystem – from frontline extraction through to investigative review – that reduces backlog, removes manual evidence handling and frees lab resources for higher-value forensic work reduce backlog.

- In addition to using its traditional Inseyets (Collect) solution, the customer added Kiosks (Collect/Field) and Guardian (Manage) for securely uploading evidence, collaborating with specialists and sharing results directly with investigating officers
- Displaced a competitive kiosk solution
- **ARR increased by 250%+**

Collect



Manage



© 2026 Cellebrite DI Ltd.


Example 02

U.S. SLG:
State Law Enforcement Agency


Helped this customer connect nearly a dozen separate divisions who previously operated in silos

- Long-standing customer who increased its usage of Guardian (Manage) earlier in 2026 to help build out a single statewide data warehouse with scalable, cloud-based storage and seamless case and evidence sharing
- Added Advanced Unlocks (Collect) to support lawful access to the most advanced smartphones
- Began using Genesis for interrogating an array of evidential artifacts
- **ARR increased ~25% in Q3 and is up 3x since FY25-Q3**


Collect



Manage



AI



© 2026 Cellebrite DI Ltd.


Example 03

Asia-Pacific:
National Military Unit

This military unit turned to Cellebrite for faster triage of mobile phones and drones obtained in the field.

- Increased spending by this customer reflects Cellebrite's intensified focus on supporting defense and intelligence use cases
- Substantial expansion of field-ready deployable data collection capabilities focused on mobile phones and drones
- **ARR increased by nearly 60%**

Collect



© 2026 Cellebrite DI Ltd.


Example 04

U.S. Federal:
National law Enforcement Agency

Substantial investment in Cellebrite technology, highlighted by the single-largest deployment of Guardian to date, supports the agency's objective of modernize digital forensics, accelerate investigations and improve collaboration across field offices

- This agency selected Cellebrite to support its initiatives around modernizing its digital forensics capabilities, increasing the speed and efficacy of its investigations and enhancing collaboration across the agency's vast footprint in the U.S. and abroad
- Broader deployment of Cellebrite's digital forensics, including advanced unlocks, new drone forensics, ongoing use of Pathfinder for multi-phone analytics, and the first major deployment of its SaaS-based Guardian by a U.S. Federal agency
- **ARR increased ~80%**


Collect



Manage



AI



© 2026 Cellebrite DI Ltd.

Example 05


Americas:

LatAm National Agency for Public Safety & Security


Ongoing expansion of Cellebrite technology to accelerate investigations that now includes Genesis, Cellebrite's agentic AI-powered solution

- This agency, a long-standing Cellebrite customer, expanded its use of Inseyets for digital forensics, Guardian for secure evidence management and collaboration, and Pathfinder deployment for on-prem multi-device analytics.
- In addition to these expansions, the agency became one of the first Latin American agencies to leverage Genesis for agentic AI-powered analysis of multi-data source evidentiary artifacts.
- **ARR increased by nearly 45%**


Collect



Manage



AI



© 2026 Cellebrite DI Ltd.

Genesis Platform For Investigations & Intelligence-led Operations



AI Analysis & Assistance

Embedded across every layer of the platform

Customer Segments

- Law Enforcement
- Defense & Intelligence
- U.S. Federal
- Enterprise

Roles Served

- Forensic Examiner
- Investigator / Detective
- Lab / Evidence Collector
- Field Operative
- Prosecutor / Legal
- Intelligence Analyst

Capabilities

- Lab Management
- Field Triage
- Evidence Collection
- Multi-Data Source Analysis
- Legal Review
- Forensic Validation
- Cross-Case Analysis
- Workflow & Collaboration

Platform Deployment

- SaaS
- On-Prem
- Field

© 2026 Cellebrite DI Ltd.

Financial Review.

© 2026 Cellebrite DI Ltd.

FY26-Q3 Result Highlights.

$528M

ARR, Sep-26: **+20%** from $440M

WHAT DROVE ARR GROWTH

Strong **international** growth

Another acceleration in **U.S. Federal**

Total revenue	Subscription revenue	Adj. EBITDA*	Rule of X, TTM Sep-26
$149M	**$135M**	**$54M**	**51**
+18% vs. $126M in FY25-Q3	**+20%** vs. $113M in FY25-Q3	**+42%** 36% margin, up from 30% in FY25-Q3 ($38M)	**from 50** FCF margin 31% + ARR growth 20%

Topline expansion + prudent spending → Adj. EBITDA* and free cash flow expansion

* Non-GAAP


Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non-GAAP metric and its most applicable GAAP measure.

© 2026 Cellebrite DI Ltd.

Sustainable ARR Growth.

FY26-Q3 Highlights

- **Sep-26 ARR grew 20%**
- **NRR 116%**
- **Gross revenue retention ~93%**



ARR ($M)

	Sep-25	Dec-25*	Mar-26	Jun-26	Sep-26
% Total ARR Growth (Y/Y)	19%	21%	21%	21%	20%


* Includes $16.1M in ARR from Corellium at the time of the acquisition.

© 2026 Cellebrite DI Ltd.


ARR Growth By Geography & ARR Geographic Mix

ARR by Geography

($ in millions)



ARR Mix by Geography




Note: Numbers may not total due to rounding

© 2026 Cellebrite DI Ltd.

Demonstrating Continued Operating Leverage


Healthy Software Gross Margin

Gross Profit (Non-GAAP, $M) and
Gross Profit Margin (Non-GAAP, %)



Driving Adj. EBITDA Improvement

Adjusted EBITDA (Non-GAAP, $M) and
Adjusted EBITDA Margin (Non-GAAP, %)



Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non-GAAP metric and its most applicable GAAP measure.


© 2026 Cellebrite DI Ltd.

Compelling Cash Generation

$593M in Cash & Investments; ~31% FCF Margin

Cash & Investments


($ in millions)



Note: Numbers may not total due to rounding

Free Cash Flow[1] & Free Cash Flow Margin

($ in millions)




1 Defined as cash flow provided by operations less capital expenditures (purchases of plant, property & equipment and capitalized software development costs)

Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non-GAAP metric and its most applicable GAAP measure.

© 2026 Cellebrite DI Ltd.

Weighted Average Shares Outstanding – Basic



- Former CEO Equity awards vested in FY26-Q3 lifting quarterly share growth
- Expecting WASO to increase each year by ~2%

© 2026 Cellebrite DI Ltd.

Financial Forecast

	FY25	FY26-Q4 EXPECTATIONS (as of 11/12/26)	FY26 EXPECTATIONS (as of11/12/26)
ARR	$480.8M	--	$550M – $560M
ARR Growth (y/y)	+21%	--	+14% – +16%
Revenue	$475.7M	$145M – $150M	$553M – $558M
Revenue Growth (y/y)	+19%	+13% – +16%	+16% – +17%
Adjusted EBITDA*	$127.6M	$47M – $50M	$163M – $166M
Adjusted EBITDA Margin*	26.8%	32% – 33%	29% – 30%

* Non-GAAP
Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non-GAAP metric and its most applicable GAAP measure

© 2026 Cellebrite DI Ltd.

Summary.

A healthy market with powerful tailwinds

Increasing wallet share with diverse, global customer base

End-to-End Platform
Genesis evolving from a purpose-built agentic AI product into an AI-native platform

Purpose-built, AI-powered technology for public safety

Proven solutions for on-premise, cloud and hybrid

Rule of X (ARR growth rate + FCF margin) performance objective of 50+

Firepower accelerate innovation and TAM expansion



© 2026 Cellebrite DI Ltd.

Financial

Appendix.

© 2026 Cellebrite DI Ltd.

Use Of Non-GAAP Financial Information.

This presentation includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP net income, non-GAAP EPS and adjusted EBITDA is helpful to investors. These measures, which the Company refers to as its non-GAAP financial measures, are not prepared in accordance with GAAP.

The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance from period to period, and offer investors and management greater visibility into the underlying performance of its business:

- Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expenses;
- Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition;
- Acquisition-related expenses and executive severance expenses relate to the cash component of contractual severance due to our former CEO and CFO, all of which are unrelated to current operations and neither are comparable to the prior period nor predictive of future results;
- To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income;
- Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performance and make period-to-period comparisons more challenging; and
- Financial income, net, consists primarily of interest income on cash and investments, and varies with cash balances and interest rates. Excluding this item enhances comparability across periods and with peers.

Free cash flow is calculated as net cash provided by or used in operating activities less purchases of property and equipment and the capitalization of software development costs (collectively referred to as capital expenditures). We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash provided by or used in our operations that, after the investments in capital expenditures, can be used for strategic initiatives.

Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, significant recurring expenses in our business and an important part of the compensation provided to our employees. In addition, the amortization of intangible assets is expected to be a recurring expense over the estimated useful life of the underlying intangible asset and acquisition-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.

A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on our website at https://investors.cellebrite.com.

In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, share-based compensation expense for future awards, tax expense, depreciation and amortization expense, and certain financing.



© 2026 Cellebrite DI Ltd.

Organic ARR (Excluding ARR Related To Acquisitions)

RECONCILIATION
FY23, FY24, FY25 by Quarter and FY26 by Quarter

Cellebrite

	FY 2023	FY 2024	FY 2025					FY 2026			
Cellebrite DI Ltd. - Revenues mix	Yr Ended	Yr Ended	Quarter Ended				Yr Ended	Quarter Ended			YTD
(U.S. Dollars in thousands - unaudited)	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sept	30-Sept
Annual recurring revenue (in thousands)											
Total ARR	**315,689**	**395,899**	408,060	418,875	439,803	480,760	**480,760**	492,970	507,771	528,452	**528,452**
ARR related to acquisitions	-	-	-	-	-	16,078	**16,078**	-	-	-	-
Organic ARR	**315,689**	**395,899**	408,060	418,875	439,803	464,682	**464,682**	492,970	507,771	528,452	**528,452**

© 2026 Cellebrite DI Ltd.

Cost of Revenue and Gross Profit

RECONCILIATION
FY23, FY24, FY25 by Quarter and FY26 by Quarter

Cellebrite

	FY 2023	FY 2024	FY 2025					FY 2026			
GAAP to Non-GAAP Reconciliations	Yr Ended	Yr Ended	Quarter Ended				Yr Ended	Quarter Ended			YTD
(U.S. Dollars in thousands, except share and per share data)	31-Dec	31-Dec	31-Mar	30-Jun	30-Sept	31-Dec	31-Dec	31-Mar	30-Jun	30-Sept	30-Sept
GAAP cost of revenue:											
Cost of revenue	**53,231**	**62,593**	17,490	17,677	20,314	19,691	**75,172**	22,420	25,207	27,975	**75,602**
Less:											
Share-based compensation expense	1,733	2,227	750	827	828	775	3,180	692	657	698	2,047
Amortization of intangible assets	-	-	-	-	-	881	881	3,612	5,536	5,945	15,093
Acquisition-related costs	52	2	-	-	-	-	-	-	1	-	1
Redomiciliation and other strategic costs	-	-	-	-	-	-	-	-	-	-	-
Non-GAAP cost of revenue	**51,446**	**60,364**	**16,740**	**16,850**	**19,486**	**18,035**	**71,111**	**18,116**	**19,013**	**21,332**	**58,461**
GAAP gross profit:											
Gross Profit	**271,879**	**338,610**	90,059	95,599	105,715	109,130	**400,503**	105,881	105,931	121,047	**332,859**
Share-based compensation expense	1,733	2,227	750	827	828	775	3,180	692	657	698	2,047
Amortization of intangible assets	-	-	-	-	-	881	881	3,612	5,536	5,945	15,093
Acquisition-related costs	52	2	-	-	-	-	-	-	1	-	1
Redomiciliation and other strategic costs	-	-	-	-	-	-	-	-	-	-	-
Non-GAAP gross profit	**273,664**	**340,839**	**90,809**	**96,426**	**106,543**	**110,786**	**404,564**	**110,185**	**112,125**	**127,690**	**350,000**

© 2026 Cellebrite DI Ltd.

Operating Expense & Operating Income

RECONCILIATION
FY23, FY24, FY25 by Quarter and FY26 by Quarter

Cellebrite

GAAP to Non-GAAP Reconciliations (U.S. Dollars in thousands, except share and per share data)	FY 2023	FY 2024	FY 2025					FY 2026			
	Yr Ended 31-Dec	Yr Ended 31-Dec	Quarter Ended 31-Mar	30-Jun	30-Sept	31-Dec	Yr Ended 31-Dec	Quarter Ended 31-Mar	30-Jun	30-Sept	YTD 30-Sept
GAAP operating expenses:											
Operating expenses	**238,642**	**281,704**	77,791	81,182	86,725	88,325	**334,023**	96,762	98,982	94,172	**289,916**
Less:											
Executive severance costs	-	1,068	-	-	574	-	574	-	-	520	520
Issuance expenses	-345	-	-	-	-	-	-	-	-	-	-
Share-based compensation expense	17,265	28,348	8,027	7,983	14,480	11,222	41,712	13,692	14,592	14,748	43,032
Amortization of intangible assets	3,347	3,349	926	931	934	1,227	4,018	1,362	1,394	1,299	4,055
Redomiciliation and other strategic costs	-	-	-	-	-	-	-	-	-	-	-
Acquisition-related costs	-7	219	-	2,066	164	1,588	3,818	109	676	1,445	2,230
Non-GAAP operating expenses	**218,382**	**248,720**	**68,838**	**70,202**	**70,573**	**74,288**	**283,901**	**81,599**	**82,320**	**76,160**	**240,079**
GAAP operating income (loss)	33,237	56,906	12,268	14,417	18,990	20,805	66,480	9,119	6,949	26,875	42,943
Executive severance costs	-	1,068	-	-	574	-	574	-	-	520	520
Issuance expenses	-345	-	-	-	-	-	-	-	-	-	-
Share-based compensation expense	18,998	30,575	8,777	8,810	15,308	11,997	44,892	14,384	15,249	15,446	45,079
Amortization of intangible assets	3,347	3,349	926	931	934	2,108	4,899	4,974	6,930	7,244	19,148
Redomiciliation and other strategic costs	-	-	-	-	-	-	-	-	-	-	-
Acquisition-related costs	45	221	-	2,066	164	1,588	3,818	109	677	1,445	2,231
Non-GAAP operating income (loss)	**55,282**	**92,119**	**21,971**	**26,224**	**35,970**	**36,498**	**120,663**	**28,586**	**29,805**	**51,530**	**109,921**

Note: This document should be read in conjunction with the Company's SEC Filings.

© 2026 Cellebrite DI Ltd.

Net Income & Adjusted EBITDA

RECONCILIATION
FY23, FY24, FY25 By Quarter and FY26 by Quarter

Cellebrite

	FY 2023	FY 2024	FY 2025					FY 2026			
GAAP to Non-GAAP Reconciliations (U.S. Dollars in thousands, except share and per share data)	Yr Ended 31-Dec	Yr Ended 31-Dec	Quarter Ended 31-Mar	30-Jun	30-Sept	31-Dec	Yr Ended 31-Dec	Quarter Ended 31-Mar	30-Jun	30-Sept	YTD 30-Sept
GAAP net income (loss)	-81,100	-283,007	17,400	19,476	20,189	21,261	78,326	10,938	6,371	26,656	43,965
Executive severance costs	-	1,068	-	-	574	-	574	-	-	520	520
One-time tax (income) expense	-	-	-	-	-	-	-	-	-	-	-
Issuance expenses	-345	-	-	-	-	-	-	-	-	-	-
Share-based compensation expense	18,998	30,575	8,777	8,810	15,308	11,997	44,892	14,384	15,249	15,446	45,079
Amortization of intangible assets	3,347	3,349	926	931	934	2,108	4,899	4,974	6,930	7,244	19,148
Redomiciliation and other strategic costs	-	-	-	-	-	-	-	-	-	-	-
Acquisition-related costs	45	221	-	2,066	164	1,588	3,818	109	677	1,445	2,231
Income tax income (expense)	633	-4,049	-924	-510	-309	-260	-2,003	215	465	-5,761	-5,081
Finance expenses (income)	119,348	349,604	-	-	-	-	-	-	-	-	-
Non-GAAP net income (loss)	**60,926**	**97,761**	**26,179**	**30,773**	**36,860**	**36,694**	**130,506**	**30,620**	**29,692**	**45,550**	**105,862**
GAAP net income (loss)	-81,100	-283,007	17,400	19,476	20,189	21,261	78,326	10,938	6,371	26,656	43,965
Financial (Income) expense	108,800	332,890	-7,060	-6,374	-5,298	-5,466	-24,198	-4,515	-4,238	-4,866	-13,619
Tax expense (income)	5,537	7,023	1,928	1,315	4,099	5,010	12,352	2,696	4,816	5,085	12,597
Depreciation and amortization	10,011	10,607	2,631	2,592	2,703	3,941	11,867	7,005	8,915	9,339	25,259
Executive severance costs	-	1,068	-	-	574	-	574	-	-	520	520
Issuance expenses	-345	-	-	-	-	-	-	-	-	-	-
Share-based compensation expense	18,998	30,575	8,777	8,810	15,308	11,997	44,892	14,384	15,249	15,446	45,079
Acquisition-related costs	45	221	-	2,066	164	1,588	3,818	109	677	1,445	2,231
Redomiciliation and other strategic costs	-	-	-	-	-	-	-	-	-	-	-
Adjusted EBITDA	**61,946**	**99,377**	**23,676**	**27,885**	**37,739**	**38,331**	**127,631**	**30,617**	**31,790**	**53,625**	**116,032**
Adjusted EBITDA margin	19.1%	24.8%	22.0%	24.6%	29.9%	29.8%	26.8%	23.9%	24.2%	36.0%	28.4%

Note: This document should be read in conjunction with the Company's SEC Filings.

© 2026 Cellebrite DI Ltd.

Free Cash Flow & Free Cash Flow Margin

RECONCILIATION
FY23, FY24, FY25 By Quarter and FY26 by Quarter

Cellebrite

	FY 2023	FY 2024	FY 2025					FY 2026			
GAAP to Non-GAAP Reconciliations	Yr Ended	Yr Ended	Quarter Ended				Yr Ended	Quarter Ended			YTD
(U.S. Dollars in thousands, except share and per share data)	31-Dec	31-Dec	31-Mar	30-Jun	30-Sept	31-Dec	31-Dec	31-Mar	30-Jun	30-Sept	30-Sept
Cash flows from operating activities	**102,058**	**132,171**	**20,878**	**32,583**	**33,272**	**86,811**	**173,544**	**19,885**	**17,589**	**56,581**	**94,055**
Less:											
Capital expenditures	-5,231	-8,566	-2,339	-3,608	-3,322	-3,956	-13,225	-3,041	-3,068	-4,784	-10,893
Free Cash Flow	**96,827**	**123,605**	**18,539**	**28,975**	**29,950**	**82,855**	**160,319**	**16,844**	**14,521**	**51,797**	**83,162**
Free Cash Flow margin	29.8%	30.8%	17.2%	25.6%	23.8%	64.3%	33.7%	13.1%	11.1%	34.8%	20.4%

Note: This document should be read in conjunction with the Company's SEC Filings.

© 2026 Cellebrite DI Ltd.

Free Cash Flow & Free Cash Flow Margin

RECONCILIATION
Trailing 12 Months ended September 30, 2023 – 2026

	FY22-Q4	FY23-Q1	FY23-Q2	FY23-Q3	TTM 9/30/2023	FY23-Q4	FY24-Q1	FY24-Q2	FY24-Q3	TTM 9/30/2024
Cash flows from operating activities	35,743	12,476	16,576	29,178	93,973	43,828	10,041	14,513	41,650	110,032
Less:										
Capital expenditures	(1,391)	(1,064)	(825)	(1,082)	(4,362)	(2,260)	(1,495)	(2,073)	(1,820)	(7,648)
Free Cash Flow	34,352	11,412	15,751	28,096	89,611	41,568	8,546	12,440	39,830	102,384
Free Cash Flow margin	46.4%	16.0%	20.5%	33.4%	29.3%	44.7%	9.5%	13.0%	37.3%	26.6%

	FY24-Q4	FY25-Q1	FY25-Q2	FY25-Q3	TTM 9/30/2025	FY25-Q4	FY26-Q1	FY26-Q2	FY26-Q3	TTM 9/30/2026
Cash flows from operating activities	65,967	20,878	32,582	33,272	152,700	86,811	19,885	17,589	56,581	180,866
Less:										
Capital expenditures	(3,178)	(2,339)	(3,608)	(3,322)	(12,447)	(3,956)	(3,041)	(3,068)	(4,784)	(14,849)
Free Cash Flow	62,789	18,539	28,974	29,950	140,253	82,855	16,844	14,521	51,797	166,017
Free Cash Flow margin	57.6%	17.2%	25.6%	23.8%	30.8%	64.3%	13.1%	11.1%	34.8%	30.9%

Note: This document should be read in conjunction with the Company's SEC Filings.

© 2026 Cellebrite DI Ltd.

Definitions.

Annual Recurring Revenue

Annual recurring revenue (“ARR”) is defined as the value of subscription-based customer agreements encompassing term-based on-premise software and cloud-based software, including those offerings delivered under a recurring consumption-based model, that are in effect at the end of the reporting period. For subscription-based agreements, ARR is calculated as the total contract value of the agreement divided by the length of the agreement, measured as of the end of the period and assuming no increases or reductions to the customer's subscription. For consumption-based cloud software subscriptions, ARR is calculated as the total contract value of the subscription divided by the length of the agreement, assuming no increases or reductions in the customer's usage rate. For agreements with a term of less than 12 months, ARR is calculated as the total contract value of the agreement, without annualization. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers, including contracts for which we are actively negotiating a subscription renewal, which continue to be included in ARR until the customer notifies the Company that it does not intend to renew. ARR is not a forecast of future subscription revenue, which can be impacted by contract start and end dates and renewal rates.

Free Cash Flow

Free Cash Flow is calculated as net cash provided by or used in operating activities less purchases of property and equipment and the capitalization of software development costs (collectively referred to as capital expenditures). We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash provided by or used in our operations that, after the investments in capital expenditures, can be used for strategic initiatives.

Subscription Revenue

Subscription revenue is defined as revenue from recurring, term-based license contracts and ongoing services related to core offerings. Subscription revenue is recognized ratably over the subscription term with a portion of revenue, related to the term-based license, recognized upfront.

© 2026 Cellebrite DI Ltd.

Customer Base & Growth Profile


Appendix.

© 2026 Cellebrite DI Ltd.

#1 End-to-End Platform

For Digital Investigations & Intelligence

$508M	ARR (6/30/26)
~7,000	Global Customers
~3M	Serious crime legally-sanctioned investigations in 2025*
#1	Solution for digital forensic examiners
1,287	Employees (6/30/26)



* Based on internal research estimates

© 2026 Cellebrite DI Ltd.

World-Class Customer Base

We've established our global footprint with meaningful room for expansion across our installed customer base

Public Sector

3000+ North American state and local accounts

15/15 U.S. cabinet executive departments

50/50 U.S. states

100+ North American federal accounts

20/20 Police departments in the 20 largest U.S. cities

27/27 Member E.U. national police

15/20* Largest European police departments

Private Sector

72/100 of The Fortune 100

10/10 of Top 10 accounting firms

8/10 of Top 10 pharma companies

9/10 of Top 10 U.S. commercial banks

8/10 of Top 10 U.S. technology companies

* 4 cities located in countries that Cellebrite does not actively participate commercially due to legal, ethical and business considerations.



© 2026 Cellebrite DI Ltd.


Growth Levers

Public Sector

- Law Enforcement
- Defense & Intelligence

Private Sector

- Enterprises
- Service Providers



© 2026 Cellebrite DI Ltd.

Market Trends, Drivers & Opportunities


Appendix.

© 2026 Cellebrite DI Ltd.

The Value of Digital Evidence.




Of crimes have a digital component[1]



Rising Confidence in Digital Evidence & Case Solvability[2]



Say digital evidence is expected be used in every case[2]



Investigators are seeing smartphones more often in cases[2]


Sources: (1) Policing: A Journal of Policy and Practice, Dec. 16, 2022
(2) Cellebrite 2026 Industry Trends Report

© 2026 Cellebrite DI Ltd.

1. Complexity & Volume




% of respondents who say the complexity of digital evidence has increased[1]



of agency managers have noted a 76% growth in digital data from devices over the past three years[2]



% of locked phones that reach the lab[1]



Agencies continue to encounter an average of 2 to 5 phones per case[1]

Sources: (1) Cellebrite 2026 Industry Trends Report
(2) Cellebrite 2025 Industry Trends Report

© 2026 Cellebrite DI Ltd.


2. Inefficient Processes



Of Investigators say the time it takes to review digital data is their biggest challenge[1]



Investigators are juggling ~10 weeks of investigative work at any given time.[1]



Delivery timelines remain extended: 50% report 1–4 weeks to provide mobile device data or a report, while 36% report one month or longer.[1]


Sources: (1) Cellebrite 2026 Industry Trends Report

© 2026 Cellebrite DI Ltd.

3. Ethics & Accountability

71%

Of managers report inadequate training as a major challenge.[1]



Nearly 70% of respondents rely on physical storage, such as portable hard drives and USB sticks, to share digital evidence[3]



Passed police reform and oversight bills since 20202


68%

Of investigators say the time required to review digital data is the biggest barrier to moving cases forward[1]


Sources: (1) Cellebrite 2026 Industry Trends Report
(2) “Police Reform Bills” (NY Times, 2021)

© 2026 Cellebrite DI Ltd.


AI & The Cloud.



of respondents who believe that AI can accelerate investigations.[1]



say that better investigative tools would alleviate caseload pressure[1]



Agencies are becoming more open to using the cloud for digital evidence – reflecting a steady shift toward cloud-based management, sharing, and storage of digital evidence.[1]



say they are using or actively exploring cloud solutions[1]

Sources: (1) Cellebrite 2026 Industry Trends Report

© 2026 Cellebrite DI Ltd.